Solesence, Inc. is a US-listed company in the personal care products industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: data-quality checks not passed.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Solesence, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months to June 2026 was $55m, down 14.0% on a year earlier, against growth of 5.8% a quarter earlier. Free-cash-flow margin rose to -0.1% from -3.7% a year earlier. Operating margin narrowed to -2.1% from 8.9%. It passes 0 of our 1 financial-health checks.
Our model value for Solesence is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 19, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Solesence, Inc.'s trailing-twelve-month revenue fell 14.0% year on year, with a free-cash-flow margin of -0.1%.
Current signal Revenue growth decelerating: TTM revenue growth slowed to -14.0% (-19.8pp vs the prior quarter), the 4th consecutive quarterly slowdown.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Nothing in Solesence, Inc.'s latest figures clears our strength thresholds.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Solesence, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.29 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | ~$0.4 ~$0.4–$0.5 | Primary model, counts double |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Solesence, Inc. with Personal Care Products in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Now |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | $0.40 | $0.72 | $0.52 | $0.73 | $0.28 | $0.85 | $4.40 | $1.13 | $0.60 | $2.44 | $1.60 | $0.86 |
| Market value | $11m | $22m | $16m | $25m | $10m | $33m | $207m | $56m | $30m | $159m | $116m | $62m |
| + Net debt (− = net cash) | −$1m | −$2m | −$2m | −$1m | −$194000 | $995000 | $2m | $5m | $6m | $6m | $13m | $12m |
| Enterprise value | $10m | $20m | $15m | $23m | $10m | $34m | $209m | $61m | $36m | $165m | $129m | $74m |
| Multiples | ||||||||||||
| Price / sales | 1.1x | 2.1x | 1.3x | 1.7x | 0.8x | 1.9x | 7.0x | 1.5x | 0.8x | 3.0x | 1.9x | 1.1x |
| Price / earnings | — | — | — | — | — | 33.1x | 89.2x | — | — | 37.5x | 64.9x | — |
| Price / free cash flow | — | — | — | — | — | — | n/m | — | — | — | — | 60.6x |
| EV / EBITDA | — | — | — | — | — | 18.3x | 69.3x | — | — | 27.2x | 52.3x | — |
Weak moat
How hard Solesence's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Cash operating profit has been a median 6.2% of total assets over 10 years.
Gross margin has been a median 26.3%, moving by 3.3 percentage points (standard deviation) across 10 years.
Operating margin has been a median -4.9%; its worst year was -16.0%.
Free cash flow was positive in 0 of 10 years, at a median -8.6% of revenue.
The diluted share count rose 74.6% over five years; stock-based pay has been a median 1.5% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (35 before it).
Next results: November 16, 2026.
No analyst estimates are published for Solesence, Inc.: too few analysts cover it.
Last 12 months −73.7%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $64m | $55m | −14.0% |
| P/S multiple | 3.7x | 1.1x | −69.6% |
| Share count | 72m | 72m | +0.8% |
Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.
Last 3 years −3.4%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $39m | $55m | +41.0% |
| P/S multiple | 1.1x | 1.1x | +1.2% |
| Share count | 48m | 72m | −32.3% |
Biggest factor: share count. Loss-making at one end, so the split uses price/sales.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| SLSN | +418% | −74% | −47% | +307% | −34% | −46% |
| Industry peers (median) | +31% | −32% | +6% | −11% | −34% | +1% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| SLSN | 83% | 42% | 25% | 50% | 50% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| SLSN | −24% | −75% | −72% | −53% | −69% | −61% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since October 29, 2015: 90% from January 4, 2022 to January 23, 2024. Getting back needed a 928% gain, reached on June 18, 2025, 512 days after the low.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 20, 2026 | +1.1% | −0.4% | +1.1% | −13.8% |
| May 12, 2026 | −12.0% | +0.4% | −20.7% | −16.7% |
| March 31, 2026 | +20.0% | +3.7% | +45.6% | +48.9% |
| November 13, 2025 | −5.7% | −1.7% | +6.2% | +4.1% |
| July 31, 2025 | −25.5% | −2.0% | −16.9% | −1.9% |
| May 7, 2025 | +19.1% | +1.1% | +40.4% | +36.2% |
| March 26, 2025 | −18.8% | −1.5% | −28.6% | −13.2% |
| October 30, 2024 | +41.4% | −2.3% | +36.1% | +104.5% |
| August 6, 2024 | −11.0% | +0.2% | −9.7% | −2.6% |
| April 23, 2024 | +17.2% | +1.1% | +36.4% | +39.4% |
| March 21, 2024 | −9.6% | +0.1% | −15.7% | +19.3% |
| March 5, 2024 | −18.8% | −0.5% | −37.5% | −3.7% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $37.5M |
| FY23 Q4 | $37.3M |
| FY24 Q1 | $37.7M |
| FY24 Q2 | $38.9M |
| FY24 Q3 | $47.8M |
| FY24 Q4 | $52.3M |
| FY25 Q1 | $57.1M |
| FY25 Q2 | $64.4M |
| FY25 Q3 | $62.1M |
| FY25 Q4 | $62.1M |
| FY26 Q1 | $60.4M |
| FY26 Q2 | $55.4M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q3 | 3.1% |
| FY23 Q4 | -0.1% |
| FY24 Q1 | -2.4% |
| FY24 Q2 | -1.0% |
| FY24 Q3 | 27.3% |
| FY24 Q4 | 40.3% |
| FY25 Q1 | 51.4% |
| FY25 Q2 | 65.7% |
| FY25 Q3 | 30.0% |
| FY25 Q4 | 18.6% |
| FY26 Q1 | 5.8% |
| FY26 Q2 | -14.0% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY23 Q3 | -9.3% |
| FY23 Q4 | -9.5% |
| FY24 Q1 | -3.8% |
| FY24 Q2 | -2.5% |
| FY24 Q3 | 7.2% |
| FY24 Q4 | 9.8% |
| FY25 Q1 | 7.5% |
| FY25 Q2 | 8.9% |
| FY25 Q3 | 2.8% |
| FY25 Q4 | 3.4% |
| FY26 Q1 | 2.0% |
| FY26 Q2 | -2.1% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY23 Q3 | -1.3% |
| FY23 Q4 | -8.2% |
| FY24 Q1 | -16.4% |
| FY24 Q2 | -13.5% |
| FY24 Q3 | -10.5% |
| FY24 Q4 | -4.9% |
| FY25 Q1 | -4.1% |
| FY25 Q2 | -3.7% |
| FY25 Q3 | -14.6% |
| FY25 Q4 | -15.2% |
| FY26 Q1 | -1.3% |
| FY26 Q2 | -0.1% |
Each dollar Solesence took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.
| Revenue | $62.1M | |
|---|---|---|
| Cost of revenue | $46M | 74.1% of revenue |
| Gross profit | $16.1M | 25.9% of revenue |
| Research and development | $4.1M | 6.6% of revenue |
| Selling, general and admin | $10.4M | 16.8% of revenue |
| Operating income | $1.6M | 2.5% of revenue |
| Net income | $1.8M | 2.9% of revenue |
| Fiscal year | 2010 Dec 2010 | 2011 Dec 2011 | 2012 Dec 2012 | 2013 Dec 2013 | 2014 Dec 2014 | 2015 Dec 2015 | 2016 Dec 2016 | 2017 Dec 2017 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | |||||||||||||||||
| Revenue | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 14 | 13 | 17 | 29 | 37 | 37 | 52 | 62 | 55 |
| Gross profit | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 6 | 9 | 8 | 8 | 16 | 16 | 15 |
| EBITDA | −3 | −2 | −1 | −2 | −1 | −0 | −1 | −0 | −2 | −2 | 2 | 3 | −2 | −3 | 6 | 2 | −0 |
| Operating income | −4 | −3 | −2 | −2 | −2 | −1 | −1 | −1 | −2 | −3 | 1 | 3 | −2 | −4 | 5 | 2 | −1 |
| Net income | −4 | −3 | −2 | −2 | −2 | −1 | −1 | −1 | −2 | −3 | 1 | 2 | −3 | −4 | 4 | 2 | −2 |
| Diluted EPS | −$0.19 | −$0.16 | −$0.10 | −$0.09 | −$0.06 | −$0.04 | −$0.04 | −$0.03 | −$0.06 | −$0.08 | $0.03 | $0.05 | −$0.05 | −$0.09 | $0.07 | $0.02 | −$0.03 |
| Growth (year on year) | |||||||||||||||||
| Revenue | — | +2.0% | +4.0% | −4.5% | +3.6% | +3.8% | +4.6% | +15.7% | +13.8% | −11.9% | +36.9% | +72.1% | +26.6% | −0.1% | +40.4% | +18.6% | −14.0% |
| EBITDA | — | — | — | — | — | — | — | — | — | — | — | +63.5% | −156.1% | — | — | −59.3% | −101.4% |
| Operating income | — | — | — | — | — | — | — | — | — | — | — | +72.3% | −188.2% | — | — | −69.4% | −120.6% |
| Net income | — | — | — | — | — | — | — | — | — | — | — | +134.6% | −213.1% | — | — | −57.7% | −134.3% |
| Diluted EPS | — | — | — | — | — | — | — | — | — | — | — | +66.7% | −200.0% | — | — | −71.4% | −134.5% |
| Margins | |||||||||||||||||
| Gross margin | 26.7% | 24.1% | 26.3% | 26.7% | 28.5% | 30.2% | 30.0% | 30.9% | 23.2% | 20.9% | 35.0% | 29.5% | 22.4% | 21.0% | 30.9% | 25.9% | 26.5% |
| EBITDA margin | −31.2% | −23.3% | −14.0% | −16.9% | −9.9% | −4.3% | −6.1% | −3.4% | −12.0% | −19.8% | 10.8% | 10.2% | −4.5% | −7.5% | 11.6% | 4.0% | −0.2% |
| Operating margin | −43.3% | −34.9% | −23.8% | −26.0% | −17.3% | −11.4% | −11.8% | −6.2% | −14.3% | −22.4% | 8.7% | 8.7% | −6.1% | −9.5% | 9.8% | 2.5% | −2.1% |
| Net margin | −43.1% | −34.9% | −23.8% | −25.8% | −17.4% | −11.6% | −11.9% | −6.3% | −14.7% | −24.0% | 5.8% | 7.9% | −7.0% | −11.8% | 8.1% | 2.9% | −3.8% |
| Free-cash-flow margin | −18.0% | −31.1% | −7.5% | −8.4% | −14.1% | −5.0% | −3.4% | −9.4% | −10.6% | −28.1% | −17.2% | 1.5% | −12.0% | −8.2% | −4.9% | −13.8% | 1.8% |
| Cash flow | |||||||||||||||||
| Cash from operations | −1 | −3 | −1 | −1 | −1 | −0 | −0 | −1 | −1 | −3 | −2 | 2 | −2 | −2 | 2 | −9 | 1 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 1 | 5 | 0 | 0 |
| Free cash flow | −2 | −3 | −1 | −1 | −1 | −1 | −0 | −1 | −2 | −4 | −3 | 0 | −4 | −3 | −3 | −9 | 1 |
| Stock-based pay | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Free cash flow after stock pay | −2 | −3 | −1 | −1 | −2 | −1 | −1 | −1 | −2 | −4 | −3 | 0 | −5 | −4 | −3 | −9 | 1 |
| Balance sheet | |||||||||||||||||
| Cash | 6 | 3 | 4 | 3 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 7 | 8 | 7 | 14 | 13 |
| Net debt (negative = net cash) | −6 | −3 | −4 | −3 | −2 | −1 | −2 | −2 | −1 | −0 | 1 | 2 | 5 | 6 | 6 | 13 | 12 |
| Diluted shares | — | 21m | 24m | 28m | 28m | 29m | 31m | 31m | 34m | 37m | 39m | 47m | 49m | 50m | 65m | 73m | 72m |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 17 | 13 | 15 | 20 | 15 | 12 | 13 | 15 |
| Gross profit | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 5 |
| EBITDA | 3 | 0 | 0 | 3 | −1 | 0 | −0 | 0 |
| Operating income | 3 | −0 | 0 | 2 | −1 | 0 | −1 | 0 |
| Net income | 3 | −1 | 0 | 3 | −1 | 0 | −1 | −0 |
| Diluted EPS | $0.04 | −$0.01 | $0.00 | $0.04 | −$0.02 | $0.00 | −$0.01 | $0.00 |
| Growth (year on year) | ||||||||
| Revenue | +111.9% | +56.9% | +48.2% | +56.1% | −13.5% | −0.7% | −11.4% | −24.7% |
| EBITDA | — | — | −64.2% | +110.7% | −116.2% | — | −180.3% | −83.6% |
| Operating income | — | — | −77.0% | +136.5% | −124.4% | — | — | −95.1% |
| Net income | — | — | −61.6% | +277.7% | −136.8% | — | −380.5% | −104.9% |
| Diluted EPS | — | — | −100.0% | +300.0% | −150.0% | — | — | −100.0% |
| Margins | ||||||||
| Gross margin | 36.2% | 22.0% | 23.1% | 31.6% | 23.1% | 27.5% | 24.2% | 31.0% |
| EBITDA margin | 20.3% | 0.0% | 3.3% | 13.3% | −3.8% | 3.3% | −3.0% | 2.9% |
| Operating margin | 19.0% | −1.8% | 1.8% | 12.2% | −5.4% | 1.5% | −5.4% | 0.8% |
| Net margin | 18.1% | −4.4% | 2.3% | 15.9% | −7.7% | 1.3% | −7.4% | −1.0% |
| Free-cash-flow margin | 16.6% | −3.2% | — | −3.2% | −17.2% | 14.6% | 11.7% | 1.2% |
| Cash flow | ||||||||
| Cash from operations | 4 | 2 | −7 | −1 | −3 | 2 | 2 | 0 |
| Capital spending | 1 | 3 | — | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | 3 | −0 | — | −1 | −3 | 2 | 2 | 0 |
| Stock-based pay | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow after stock pay | 3 | −1 | — | −1 | −3 | 2 | 1 | 0 |
| Last 12 months unless stated | SLSN | FTLF | NHTC | AXIL | MTEX | YCBD | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $55m | $36m | $34m | $30m | $107m | $21m | $862m |
| Revenue growth, last 12 months | −14.0% | −43.3% | −16.5% | 10.3% | −5.0% | 10.0% | 3.4% |
| Revenue growth, 3-year average | 12.1% | −3.0% | −9.1% | −5.7% | −7.7% | −7.3% | −0.0% |
| Revenue growth, latest quarter | −24.7% | 64.6% | −20.2% | −11.2% | 3.8% | 20.6% | 2.1% |
| Gross margin | 26.5% | 34.8% | 74.3% | 72.4% | 76.1% | 57.7% | 66.5% |
| Operating margin | −2.1% | 10.9% | −5.9% | 10.0% | 2.5% | −13.9% | 6.3% |
| Operating margin, 3-year average | 1.4% | 16.0% | −4.1% | 6.9% | 0.4% | −37.2% | 5.3% |
| Net margin | −3.8% | 5.4% | −4.2% | 9.3% | −6.9% | −13.8% | 3.1% |
| Cash from operations / revenue | 1.8% | 28.1% | −12.3% | 14.9% | 2.3% | −10.6% | 9.6% |
| Free-cash-flow margin | −0.1% | 28.0% | −13.7% | 14.5% | 1.5% | −11.5% | 8.0% |
| Free-cash-flow margin, 3-year average | −5.8% | 17.7% | −11.4% | 7.1% | −1.0% | −7.8% | 5.6% |
| Stock pay / revenue | 0.9% | 0.1% | 0.1% | 4.3% | 0.4% | 4.2% | 1.0% |
| Change in share count | −0.8% | 0.5% | −15.7% | −5.5% | 1.2% | — | −0.1% |
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $61.8M | 99.6% | ▲ 19.1% |
| Consumer Products (part of Products) | $54.9M | 88.8% | ▲ 23.7% |
| Personal Care Ingredients (part of Products) | $6.3M | 10.3% | ▼ 7.1% |
| Advanced Materials (part of Products) | $857,000 | 1.4% | ▼ 25.3% |
| Other | $270,000 | 0.4% | ▼ 40.9% |
From Solesence, Inc.'s 10-K filed March 31, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Vanguard Capital Management LLC | $610,423 | 831K | 26.3% | ▲ 2.3% |
| Blackrock, Inc. | $340,784 | 464K | 14.7% | ▼ 56.6% |
| Bank Of New York Mellon Corp | $233,443 | 318K | 10.1% | ▲ 620.6% |
| Millennium Management LLC | $203,225 | 276K | 8.7% | New |
| Geode Capital Management, LLC | $175,352 | 239K | 7.5% | ▼ 47.2% |
| Morgan Stanley | $138,767 | 189K | 6.0% | ▼ 3.1% |
| Donaldson Capital Management, LLC | $110,250 | 150K | 4.7% | New |
| Susquehanna International Group, LLP | $81,835 | 111K | 3.5% | ▲ 697.7% |
| Vanguard Fiduciary Trust Co | $78,419 | 107K | 3.4% | ▼ 13.3% |
| Jane Street Group, LLC | $73,048 | 99K | 3.1% | New |
| Goldman Sachs Group Inc | $68,211 | 93K | 2.9% | ▲ 236.0% |
| Tower Research Capital LLC (TRC) | $40,627 | 55K | 1.7% | ▲ 363.4% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Solesence, Inc.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Whitmore R Janet Director | December 24, 2025 | Buy | 1,500 | $1.91 | $2,865 |
| Whitmore R Janet Director | December 24, 2025 | Buy | 1,000 | $1.92 | $1,920 |
| Whitmore R Janet Director | November 19, 2025 | Buy | 5,000 | $1.89 | $9,450 |
| Whitmore R Janet Director | November 19, 2025 | Buy | 5,000 | $1.95 | $9,750 |
| Whitmore R Janet Director | November 18, 2025 | Buy | 267 | $1.83 | $489 |
| Whitmore R Janet Director | November 17, 2025 | Buy | 5,000 | $1.87 | $9,350 |
| Whitmore R Janet Director | November 14, 2025 | Buy | 19,789 | $1.73 | $34,235 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
